What separates a credible life sciences company from the rest.

I have spent eleven years building operations in highly regulated industries that move fast and attract capital before the science is settled. Cannabis in 2013. Psychedelics now. The pattern is recognizable. I want to describe what I have learned to distinguish from within.

This is not a list of red flags. It is a framework for thinking about organizational credibility in contexts where hype is incentivized and verification is hard. Investors and patients both need it, for different reasons.

Why credibility is harder to assess in this field

In most industries, track record is the primary credibility signal. A pharmaceutical company has a pipeline history. A device maker has cleared products. A biotech has a published evidence base. You can look things up.

In early-stage psychedelic medicine, track records are short. Many of the most prominent operators are less than five years old. The science is promising but not yet settled. The regulatory pathway is uncertain. And the cultural moment around psychedelics creates a specific kind of noise: people who are genuinely excited about the potential of these compounds, expressing that excitement in ways that exceed what the evidence currently supports.

This is not necessarily cynical. People in the cannabis industry in 2013 were genuinely excited about what cannabis could do for patients and for operators. Some of that excitement was warranted. Some of it was not. The companies that survived were the ones that built operations on the things that were actually true.

Seven signals I use

1. How they talk about evidence.

The most reliable early signal of organizational credibility is how a leadership team discusses the evidence base for their approach. Do they distinguish between Phase 2 and Phase 3 results? Do they name the limitations of open-label data? Do they acknowledge the blinding problem? Do they cite sources?

I am not looking for humility as a performance. I am looking for precision as a habit. People who are building on solid science tend to talk about it with more nuance, not less, because they understand what the science actually says. People who are building on narrative tend to speak in broader terms about "the promise" of the therapy.

2. Who they hire as scientific advisors.

Scientific advisory boards in early-stage companies often function as credibility signals rather than actual governance. The question is not whether a company has impressive advisors listed on their website. The question is whether those advisors are actively engaged, and whether the company's practices reflect their guidance.

Advisors who publish in the field, who are willing to be quoted on specifics, and who have a track record of rigorous work are different from advisors who are lending their name to a PDF. You can often tell the difference by whether the company can produce substantive evidence of the advisor's involvement when asked.

3. The integrity of their clinical claims.

This is the clearest signal and the one most often overlooked. When a company makes a clinical claim, cite the source. Not the press release. The study. Then read the study.

Claims that go beyond what the cited study actually shows are a significant credibility marker. This applies to efficacy claims, safety claims, and mechanism claims. "Our therapy has shown 70% response rates" is a claim that requires a denominator, a definition of response, and a description of the population and comparator.

4. How they handle setbacks.

Most promising drugs fail at some point in development. Most operators encounter regulatory obstacles, clinical challenges, and commercial setbacks. How a leadership team communicates those setbacks is informative.

Companies that describe setbacks as "opportunities to learn," provide substantive explanation of what they learned and how it changes their approach, and maintain consistency between their public communications and their actual operational decisions are demonstrating something real. Companies that become quiet after bad news, or that use investor relations language to obscure what happened, are showing you something different.

5. Operational infrastructure, not just scientific narrative.

Credible companies in regulated industries build operational infrastructure before they need it. Quality management systems, regulatory affairs capacity, pharmacovigilance processes, training programs, and compliance functions exist because these organizations know that they will need them.

Companies that run thin on operations while maintaining heavy investment in marketing and communications are telling you something about their theory of value creation. In regulated industries, operational credibility is not separable from scientific credibility.

6. Patient centricity in practice.

The psychedelic medicine field often talks about patient centricity. The actual signals are specific: Does the company have patient reported outcome measures as primary or co-primary endpoints in their trials? Does their informed consent process reflect the known risks, including psychological distress and contraindications? Does their commercial model create barriers for the patients who are most likely to benefit?

Patient centricity in practice is different from patient centricity in brand positioning. The former shows up in protocols, consent documents, and pricing structures. The latter shows up in testimonials and social media.

7. Engagement with the broader field.

Credible organizations in early-stage science contribute to the commons. They publish, present, and engage with the research community. They share negative findings as well as positive ones. They participate in working groups on standards and protocols.

Organizations that are primarily consumers of the scientific commons, building commercial products on publicly funded research without contributing back, are not necessarily bad actors. But their posture tells you something about their relationship to the evidence base.

For investors

If you are allocating capital to this space, the framework above is not sufficient diligence, but it is a useful filter. The companies worth deeper attention are the ones that can demonstrate all seven signals with specificity, not generality.

The question I ask at the end of any meeting with a psychedelic medicine company is this: what would you need to see in the next major trial to change your view of your approach? A company with a credible answer to that question is a company building on science. A company that cannot engage with that question is a company building on belief.

Both can generate returns in certain market conditions. Only one of them is building something durable.

For patients

The signals that matter most for patients are different from the signals that matter for investors. The questions I would ask:

• What is the evidence base for this specific intervention, in a population like mine, for a condition like mine?
• What are the known contraindications and adverse events?
• What happens if I have a difficult experience?
• Who trained the practitioners, and what is the training curriculum?
• Is this company or practitioner willing to give me a citation for any claim they make about efficacy or safety?

None of these questions should be difficult for a credible practitioner to answer. Difficulty in answering them is itself informative.

The field is producing real science. Some of the operators in it are building on that science rigorously. Finding those operators requires the same skills as reading a clinical trial: go to the primary source, check the claims against the evidence, and name the gap between the two when it exists.

If you want this kind of analysis every week, the signup is below.

Subscribe to Psilosignal